MARKET

PRTCY

PRTCY

Puretech Health
OTCPK
15.93
-0.18
-1.12%
Closed 09:48 07/07 EDT
OPEN
15.93
PREV CLOSE
16.11
HIGH
15.93
LOW
15.93
VOLUME
1
TURNOVER
16
52 WEEK HIGH
19.92
52 WEEK LOW
14.50
MARKET CAP
387.77M
P/E (TTM)
-3.4953
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PRTCY last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at PRTCY last week (0622-0626)?
Weekly Report · 06/29 10:13
Weekly Report: what happened at PRTCY last week (0615-0619)?
Weekly Report · 06/22 10:21
Weekly Report: what happened at PRTCY last week (0608-0612)?
Weekly Report · 06/15 10:22
Weekly Report: what happened at PRTCY last week (0601-0605)?
Weekly Report · 06/08 10:18
PureTech Health (PRTC) Has a New Rating from Investec
TipRanks · 06/03 00:28
Weekly Report: what happened at PRTCY last week (0525-0529)?
Weekly Report · 06/01 10:23
Weekly Report: what happened at PRTCY last week (0518-0522)?
Weekly Report · 05/25 10:26
More
About PRTCY
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Webull offers PureTech Health PLC (ADR) stock information, including OTCPK: PRTCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTCY stock methods without spending real money on the virtual paper trading platform.